Delivery Order SPE2DB22D2009-SPE2DB24FL6HK
- Not listed
- This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The $16,089.10 firm-fixed-price delivery order is for the supply of 4,564,082,832 units of the pharmaceutical product Rifampin 300 mg capsules. The contract has an ultimate completion date of March 27, 2024. Amerisourcebergen Drug Corp is a major pharmaceutical distributor that plays a critical role in supplying medical products to federal government...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, a leading global pharmaceutical sourcing and distribution services company. The contract, a delivery order with a firm fixed price, has a ceiling value of $2,042.53 and a completion date of April 11, 2024. The contract is for the provision of Rifampin 300 mg capsules, a specialty pharmaceutical product. Amerisourcebergen Drug Corp serves as...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Rifampin 300 mg capsules. The $2,810.16 firm-fixed-price contract has a completion date of January 11, 2023. The award is not designated as a set-aside contract. AmerisourceBergen Drug Corp is a subsidiary of the parent company Cencora, Inc., which maintains a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop...
- The U.S. Defense Logistics Agency (DLA) has awarded a $29,964.06 firm-fixed-price delivery order contract to Amerisourcebergen Drug Corp for the supply of 4,565,470 units of Rifampin 300 mg capsules. This delivery order is part of a larger Indefinite Delivery Contract (IDC) between the DLA Troop Support Medical and Amerisourcebergen, valued at up to $999,999,999 through December 2025, for the provision of a comprehensive range of medical commodities to support military treatment programs and...
- The U.S. Defense Logistics Agency (DLA) awarded a delivery order valued at $27,852.48 to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of Rifampin 300 mg capsules. This delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 held by Amerisourcebergen with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military...
- This federal contract award, with ID SPE2DB22D3011|SPE2DB24FP9SU, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The $25,173.41 firm-fixed-price delivery order is for the supply of 4563906298 - Rifampin 300 mg Capsule, 60s. The award is not associated with a set-aside program and has an ultimate completion date of March 11, 2024. Amerisourcebergen Drug Corp is a major pharmaceutical distributor that holds significant Indefinite...
- The U.S. Department of Defense (DoD) Defense Logistics Agency (DLA) Troop Support Medical awarded a $4,504.35 firm fixed-price delivery order to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., for the supply of 4559012573 - Rifampin 150 mg Capsule 30s. This delivery order is part of a larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued up to $999,999,999.00 through December 2025, for the comprehensive delivery of pharmaceutical products and medical...
- This is a federal contract award from the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order valued at $1,265.78 for the supply of 60 capsules of Rifampin 300 mg. The contract has a completion date of May 30, 2024 and is a Firm Fixed Price contract. This award is associated with a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen and the DLA Troop Support...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $25,106.91 firm fixed-price delivery order is for the supply of 4564959699 Rifampin 300 mg capsules. The award does not have a set-aside designation, indicating open competition. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary...
- This federal contract award, valued at $14,304.78, was issued by the Defense Logistics Agency (DLA) Troop Support Medical to the prime contractor Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of Rifampin 300 mg capsules in 60-count packages. This award is part of a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen's parent company, Cencora, Inc., with the DLA Troop Support Medical, valued at up to $999,999,999.00 and running...
- SPE2DB22D2009Indefinite Delivery Contract
- SPE2DB22D2009-SPE2DB24FL6HKDelivery Order
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The contract is a Delivery Order (SPE2DB22D2009|SPE2DB24FL6HK) for the supply of 4562677244 - Rifampin 300 mg Capsules, with an ultimate completion date of November 2, 2023 and a ceiling value of $8,878.88. The contract is not set aside and was awarded under full and open competition. Amerisourcebergen Drug Corp, as a major pharmaceutical distributor, has a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued up to $999,999,999.00, which serves as the primary vehicle for the company to deliver a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. This current delivery order is likely part of that larger IDC framework.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $8.9k | 11/1/23 |